Brief: Hemostemix Announces Departure Of David Berman As CFO
03/05/2018 13:39
May 3 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX ANNOUNCES FIRST PATIENT TREATED IN PHASE II
CLINICAL
TRIAL
* HEMOSTEMIX INC - ANNOUNCES DEPARTURE OF DAVID BERMAN FROM
POSITION OF CHIEF FINANCIAL OFFICER
* HEMOSTEMIX INC - KRISTIN GULKA JOINS HEMOSTEMIX IN
CAPACITY OF
CFO
Source text for Eikon: ID:nGNX3J58CX
Further company coverage: HEM.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update